Unknown PHASE3 INTERVENTIONAL 2-arm NCT04135781

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Adjuvant Nab-paclitaxel Plus S-1 Versus Capecitabine Plus Oxaliplatin for Patients With Stage III Gastric Cancer After D2 Gastrectomy : a Randomised，Open-label, Phase III Study

Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Conditions Stomach Cancer

Interventions Capecitabine Oxaliplatin Tegafur nab paclitaxel

Updated 6 times since 2019 Last updated: Mar 18, 2020 Started: Mar 1, 2020 Primary completion: Oct 31, 2024 Completion: Oct 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04135781, this PHASE3 trial focuses on Stomach Cancer and remains ongoing. Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd., it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Dec 2024 — Present [monthly]

Unknown PHASE3

Status: Recruiting → Unknown
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE3
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Nov 2019 — Apr 2020 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC Ouyi Pharmaceutical Co., Ltd.
Zhejiang Cancer Hospital

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China